CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 116 enrolled
Drug / intervention
Influenza Virus Vaccine (2006-2007 Fluzone® vaccine) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00389532
NCT00389532Phase 4Completed

Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2006-2007 Formulation)

Sanofi Pasteur, a Sanofi Company·interventional·Posted Oct 19, 2006·Updated Apr 14, 2016

In Brief

A Phase 4 clinical trial evaluating Influenza Virus Vaccine (2006-2007 Fluzone® vaccine) for Influenza. Completed, enrolled 116 participants across 1 site.

Detailed Summary

To submit remaining available sera to Center for Biologics Evaluation and Research (CBER) for further analysis by the Food and Drug Administration (FDA), the Center for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to support selection and recommendation of antigen strains for subsequent influenza vaccines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 19, 2006
Enrollment StartOct 1, 2006
Primary CompletionApr 1, 2008
Study CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.7 years ago

Interventions

Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)biological

Influenza vaccine

Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)biological

Influenza vaccine